Beam Therapeutics Inc. BEAM
BEAM among the 162 companies we cover
Where it stands · the better end on the right. The band holds the middle half; the line is the median.
BEAM and 9 peers, year by year
The 9 Health care companies closest to BEAM in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.
Choose the peers
| Company | Year | Revenue | Sales growth | Operating margin | Net margin | FCF margin | Return on equity | Debt / equity |
|---|---|---|---|---|---|---|---|---|
| BEAM Beam Therapeutics Inc. | FY2025 | $139.7M | +120% | −274.6% | −57.2% | −257.7% | −6.5% | - |
| AGIO Agios Pharmaceuticals, Inc. | FY2025 | $54.0M | +48.0% | −873.9% | −764.0% | −698.3% | −34.6% | - |
| GRAL GRAIL, Inc. | FY2025 | $147.2M | +17.2% | −382.0% | −277.5% | −203.8% | −15.8% | - |
| CYTK Cytokinetics Inc | FY2025 | $88.0M | +377% | −695.4% | −891.6% | −607.5% | n/m | n/m |
| KYMR Kymera Therapeutics, Inc. | FY2025 | $39.2M | −16.7% | −891.1% | −794.0% | −597.6% | −19.7% | - |
| RVMD Revolution Medicines, Inc. | FY2025 | $0 | - | - | - | - | −69.3% | - |
| RXRX Recursion Pharmaceuticals, Inc. | FY2025 | $74.7M | +26.9% | −867.9% | −863.4% | −506.5% | −57.0% | 0.02 |
| OCUL Ocular Therapeutix, Inc | FY2025 | $52.0M | −18.5% | −519.8% | −511.9% | −417.5% | −40.6% | 0.11 |
| ROIV Roivant Sciences Ltd. | FY2026 | $8.3M | −71.6% | n/m | n/m | n/m | −6.6% | - |
| LGND Ligand Pharmaceuticals Inc | FY2025 | $268.1M | +60.4% | 15.3% | 46.4% | 18.2% | 12.2% | - |
Each company, year by year
Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2019 to FY2025 · 10-K XBRL
Who rewrote the most
Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before
Revenue, FY2019 to FY2025
Revenue as reported in the 10-K.
| Company | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| BEAM Dec | $18K | $24K | $51.8M | $60.9M | $377.7M | $63.5M | $139.7M |
| AGIO Dec | $117.9M | $0 | $0 | $14.2M | $26.8M | $36.5M | $54.0M |
| GRAL Dec | - | - | - | $55.5M | $93.1M | $125.6M | $147.2M |
| CYTK Dec | $26.9M | $55.8M | $70.4M | $94.6M | $7.5M | $18.5M | $88.0M |
| KYMR Dec | $2.9M | $34.0M | $72.8M | $46.8M | $78.6M | $47.1M | $39.2M |
| RVMD Dec | $50.0M | $43.0M | $29.4M | $35.4M | $11.6M | $0 | $0 |
| RXRX Dec | $2.3M | $4.0M | $10.2M | $39.8M | $44.6M | $58.8M | $74.7M |
| OCUL Dec | $4.2M | $17.4M | $43.5M | $51.5M | $58.4M | $63.7M | $52.0M |
| ROIV Mar | - | - | $23.8M | $55.3M | $31.5M | $32.7M | $29.1M |
| LGND Dec | $120.3M | $163.6M | $241.5M | $196.2M | $131.3M | $167.1M | $268.1M |
| Peer median | $26.9M | $34.0M | $36.5M | $51.5M | $44.6M | $47.1M | $54.0M |
Sales growth, FY2019 to FY2025
Revenue against the fiscal year before.
| Company | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| BEAM Dec | - | +33.3% | n/m | +17.5% | +520% | −83.2% | +120% |
| AGIO Dec | +24.9% | −100% | - | - | +88.4% | +36.1% | +48.0% |
| GRAL Dec | - | - | - | - | +67.6% | +34.9% | +17.2% |
| CYTK Dec | −14.7% | +108% | +26.2% | +34.3% | −92.0% | +145% | +377% |
| KYMR Dec | - | n/m | +114% | −35.7% | +67.8% | −40.1% | −16.7% |
| RVMD Dec | +148% | −14.1% | −31.6% | +20.4% | −67.3% | −100% | - |
| RXRX Dec | - | +70.8% | +157% | +291% | +11.9% | +32.0% | +26.9% |
| OCUL Dec | +112% | +312% | +150% | +18.3% | +13.5% | +9.0% | −18.5% |
| ROIV Mar | - | - | - | +132% | +10.8% | +3.8% | −11.2% |
| LGND Dec | −52.2% | +55.0% | +47.7% | −18.8% | −33.1% | +27.3% | +60.4% |
| Peer median | +24.9% | +62.9% | +80.8% | +20.4% | +11.9% | +27.3% | +22.1% |
Operating margin, FY2019 to FY2025
Operating income / revenue.
| Company | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| BEAM Dec | n/m | n/m | −757.0% | −555.6% | −46.7% | −654.3% | −274.6% |
| AGIO Dec | −268.2% | - | - | n/m | n/m | n/m | −873.9% |
| GRAL Dec | - | - | - | n/m | n/m | n/m | −382.0% |
| CYTK Dec | −368.0% | −168.3% | −264.5% | −342.8% | n/m | n/m | −695.4% |
| KYMR Dec | n/m | −136.1% | −138.0% | −344.4% | −210.6% | −555.8% | −891.1% |
| RVMD Dec | −108.2% | −257.5% | −639.7% | −730.0% | n/m | - | - |
| RXRX Dec | n/m | n/m | n/m | −616.7% | −785.3% | −814.1% | −867.9% |
| OCUL Dec | n/m | −361.1% | −179.3% | −152.7% | −141.0% | −269.6% | −519.8% |
| ROIV Mar | - | - | n/m | n/m | n/m | n/m | n/m |
| LGND Dec | 671.0% | 22.9% | 43.0% | 1.5% | 9.1% | −13.5% | 15.3% |
| Peer median | −188.2% | −168.3% | −179.3% | −343.6% | −175.8% | −412.7% | −695.4% |
Net margin, FY2019 to FY2025
Net income / revenue.
| Company | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| BEAM Dec | n/m | n/m | −714.9% | −474.5% | −35.1% | −593.1% | −57.2% |
| AGIO Dec | −349.0% | - | - | n/m | n/m | n/m | −764.0% |
| GRAL Dec | - | - | - | n/m | n/m | n/m | −277.5% |
| CYTK Dec | −452.9% | −228.0% | −305.7% | −411.2% | n/m | n/m | −891.6% |
| KYMR Dec | n/m | −134.0% | −137.6% | −330.6% | −187.0% | −475.6% | −794.0% |
| RVMD Dec | −95.2% | −251.6% | −636.6% | −703.0% | n/m | - | - |
| RXRX Dec | n/m | n/m | n/m | −601.0% | −736.0% | −788.0% | −863.4% |
| OCUL Dec | n/m | −894.3% | −15.1% | −138.0% | −138.1% | −303.7% | −511.9% |
| ROIV Mar | - | - | n/m | n/m | n/m | n/m | −592.0% |
| LGND Dec | 523.2% | −1.8% | 23.7% | −17.0% | 39.7% | −2.4% | 46.4% |
| Peer median | −222.1% | −228.0% | −137.6% | −370.9% | −162.6% | −389.6% | −678.0% |
Free cash flow, FY2019 to FY2025
Cash from operations minus capital spending.
| Company | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| BEAM Dec | −$84.5M | −$112.1M | −$113.1M | −$26.4M | −$182.9M | −$356.2M | −$360.0M |
| AGIO Dec | −$382.6M | −$304.9M | −$413.1M | −$314.4M | −$297.1M | −$391.5M | −$377.3M |
| GRAL Dec | - | - | - | −$584.2M | −$608.7M | −$582.4M | −$299.9M |
| CYTK Dec | −$93.5M | −$2.1M | −$191.4M | −$310.9M | −$415.7M | −$399.8M | −$534.8M |
| KYMR Dec | $17.4M | $79.0M | −$130.5M | −$155.9M | −$137.3M | −$207.3M | −$234.3M |
| RVMD Dec | −$52.2M | −$103.0M | −$153.7M | −$235.2M | −$358.3M | −$567.7M | −$913.7M |
| RXRX Dec | −$61.0M | −$51.2M | −$198.4M | −$120.6M | −$299.7M | −$372.9M | −$378.3M |
| OCUL Dec | −$79.8M | −$54.4M | −$66.7M | −$63.3M | −$76.3M | −$136.0M | −$216.9M |
| ROIV Mar | - | - | −$557.9M | −$695.2M | −$856.1M | −$766.6M | −$844.0M |
| LGND Dec | −$31.9M | $50.1M | $70.0M | $119.9M | $46.1M | $95.2M | $48.9M |
| Peer median | −$61.0M | −$51.2M | −$172.6M | −$235.2M | −$299.7M | −$391.5M | −$377.3M |
FCF margin, FY2019 to FY2025
Free cash flow / revenue.
| Company | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| BEAM Dec | n/m | n/m | −218.1% | −43.4% | −48.4% | −560.8% | −257.7% |
| AGIO Dec | −324.5% | - | - | n/m | n/m | n/m | −698.3% |
| GRAL Dec | - | - | - | n/m | −653.8% | −463.7% | −203.8% |
| CYTK Dec | −348.1% | −3.8% | −271.8% | −328.6% | n/m | n/m | −607.5% |
| KYMR Dec | 592.1% | 232.2% | −179.2% | −333.0% | −174.7% | −440.5% | −597.6% |
| RVMD Dec | −104.3% | −239.6% | −523.0% | −664.8% | n/m | - | - |
| RXRX Dec | n/m | n/m | n/m | −302.6% | −672.4% | −633.7% | −506.5% |
| OCUL Dec | n/m | −312.6% | −153.4% | −123.0% | −130.6% | −213.4% | −417.5% |
| ROIV Mar | - | - | n/m | n/m | n/m | n/m | n/m |
| LGND Dec | −26.5% | 30.6% | 29.0% | 61.1% | 35.1% | 57.0% | 18.2% |
| Peer median | −104.3% | −3.8% | −179.2% | −315.6% | −174.7% | −440.5% | −506.5% |
Return on equity, FY2019 to FY2025
Net income / shareholders' equity at the year end.
| Company | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| BEAM Dec | n/m | −79.2% | −44.8% | −39.4% | −13.5% | −51.4% | −6.5% |
| AGIO Dec | −64.2% | −81.9% | 124.2% | −21.1% | −43.4% | 43.7% | −34.6% |
| GRAL Dec | - | - | - | - | - | −81.0% | −15.8% |
| CYTK Dec | n/m | −112.3% | −88.3% | n/m | n/m | n/m | n/m |
| KYMR Dec | n/m | −16.1% | −21.8% | −31.6% | −37.2% | −26.8% | −19.7% |
| RVMD Dec | n/m | −22.8% | −31.0% | −36.3% | −23.9% | −26.5% | −69.3% |
| RXRX Dec | n/m | n/m | −34.3% | −49.3% | −70.8% | −44.8% | −57.0% |
| OCUL Dec | n/m | n/m | −7.4% | n/m | −88.6% | −61.4% | −40.6% |
| ROIV Mar | - | - | −45.0% | −51.0% | −87.2% | 72.9% | −3.7% |
| LGND Dec | 82.0% | −0.4% | 7.0% | −5.6% | 7.4% | −0.5% | 12.2% |
| Peer median | - | −22.8% | −26.4% | −33.9% | −43.4% | −26.6% | −27.2% |
Debt / equity, FY2019 to FY2025
Total debt / shareholders' equity at the year end.
| Company | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| BEAM Dec | - | - | - | - | - | - | - |
| AGIO Dec | - | - | - | - | - | - | - |
| GRAL Dec | - | - | - | - | - | - | - |
| CYTK Dec | n/m | 0.41 | 0.19 | n/m | n/m | n/m | n/m |
| KYMR Dec | - | - | - | - | - | - | - |
| RVMD Dec | - | - | - | - | - | - | - |
| RXRX Dec | - | n/m | 0.00 | 0.00 | 0.00 | 0.03 | 0.02 |
| OCUL Dec | n/m | 0.33 | 0.28 | 0.71 | 0.72 | 0.22 | 0.11 |
| ROIV Mar | - | - | 0.09 | 0.13 | 0.32 | 0.07 | - |
| LGND Dec | - | - | - | - | - | - | - |
| Peer median | - | - | 0.14 | 0.13 | 0.32 | 0.07 | - |
EPS (diluted), FY2019 to FY2025
Diluted earnings per share, on today's share count after splits.
| Company | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| BEAM Dec | −$14.05 | −$4.19 | −$5.77 | −$4.13 | −$1.72 | −$4.58 | −$0.81 |
| AGIO Dec | −$6.86 | −$4.74 | $26.55 | −$4.23 | −$6.33 | $11.64 | −$7.12 |
| GRAL Dec | - | - | - | −$173.89 | −$47.21 | −$63.54 | −$11.11 |
| CYTK Dec | −$2.11 | −$1.97 | −$2.80 | −$4.33 | −$5.45 | −$5.26 | −$6.54 |
| KYMR Dec | −$24.28 | −$3.15 | −$2.09 | −$2.87 | −$2.52 | −$2.98 | −$3.69 |
| RVMD Dec | −$22.33 | −$2.01 | −$2.57 | −$3.08 | −$3.86 | −$3.58 | −$5.95 |
| RXRX Dec | −$2.87 | −$3.99 | −$1.49 | −$1.36 | −$1.58 | −$1.69 | −$1.44 |
| OCUL Dec | −$1.91 | −$2.56 | −$0.98 | −$0.97 | −$1.02 | −$1.22 | −$1.42 |
| ROIV Mar | - | - | −$1.28 | −$1.26 | −$1.42 | $5.23 | −$0.24 |
| LGND Dec | $31.85 | −$0.18 | $3.31 | −$1.98 | $2.94 | −$0.22 | $6.13 |
| Peer median | −$2.87 | −$2.56 | −$1.39 | −$2.87 | −$2.52 | −$1.69 | −$3.69 |
Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out BEAM and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more
Sources
Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.
Also
Financials: BEAM's own statements, year by year. Compare: the whole peer group on one page.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BEAM/export.csv") into a cell.